ES2487465T1 - Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos - Google Patents

Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos Download PDF

Info

Publication number
ES2487465T1
ES2487465T1 ES12723442.5T ES12723442T ES2487465T1 ES 2487465 T1 ES2487465 T1 ES 2487465T1 ES 12723442 T ES12723442 T ES 12723442T ES 2487465 T1 ES2487465 T1 ES 2487465T1
Authority
ES
Spain
Prior art keywords
cells
cell population
multiple sclerosis
myelin
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES12723442.5T
Other languages
English (en)
Spanish (es)
Inventor
Olga De La Rosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tigenix SA
Original Assignee
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix SA filed Critical Tigenix SA
Publication of ES2487465T1 publication Critical patent/ES2487465T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES12723442.5T 2011-05-19 2012-05-18 Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos Pending ES2487465T1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166808 2011-05-19
EP11166808 2011-05-19
PCT/EP2012/059313 WO2012156522A1 (en) 2011-05-19 2012-05-18 Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Publications (1)

Publication Number Publication Date
ES2487465T1 true ES2487465T1 (es) 2014-08-20

Family

ID=46149436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12723442.5T Pending ES2487465T1 (es) 2011-05-19 2012-05-18 Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos

Country Status (6)

Country Link
US (1) US20140348808A1 (enExample)
EP (1) EP2710122B1 (enExample)
JP (2) JP2014515258A (enExample)
KR (1) KR20140071277A (enExample)
ES (1) ES2487465T1 (enExample)
WO (1) WO2012156522A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290736B2 (en) * 2009-11-04 2016-03-22 Case Western Reserve University Compositions and methods of treating T cell mediated disorder
FR2976580B1 (fr) * 2011-06-14 2013-05-31 Coatex Sas Epaississants non ioniques associatifs contenant des alkyls cyclohexylols, formulations les contenant et leurs utilisations.
EP3551749B1 (en) 2016-12-07 2023-09-27 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
EP3773629A4 (en) * 2018-03-27 2022-01-19 AZTherapies, Inc. CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN109913415B (zh) * 2019-03-26 2020-05-22 广东先康达生物科技有限公司 Treg细胞的培养液及其培养方法与应用
IL311185A (en) * 2021-09-03 2024-04-01 Sangamo Therapeutics Inc MOG-binding proteins and uses thereof
CN120129527A (zh) * 2022-09-02 2025-06-10 财团法人医药工业技术发展中心 包含间充质干细胞的组合物在缓解骨髓纤维化上的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性t細胞は自己免疫を抑制する
WO2007014420A1 (en) * 2005-08-02 2007-02-08 Centenary Institute Of Cancer Medicine And Cell Biology Method for identifying regulatory t cells
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20100291117A1 (en) * 2009-05-18 2010-11-18 Tinghua Cao Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
US20140348808A1 (en) 2014-11-27
EP2710122B1 (en) 2021-03-31
JP2018134086A (ja) 2018-08-30
JP6592551B2 (ja) 2019-10-16
WO2012156522A1 (en) 2012-11-22
EP2710122A1 (en) 2014-03-26
KR20140071277A (ko) 2014-06-11
JP2014515258A (ja) 2014-06-30

Similar Documents

Publication Publication Date Title
US12545889B2 (en) Colony forming medium and use thereof
Chen et al. The application of umbilical cord‐derived MSCs in cardiovascular diseases
ES2927175T3 (es) Método de producción de micropartículas
ES3032663T3 (en) Stem cell microparticles and mirna
ES2769778T3 (es) Composiciones inmunomoduladoras
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
BR112018003031A2 (pt) formulações clínicas
MX2016010171A (es) Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas.
PL2102331T3 (pl) Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
MX342474B (es) Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
WO2008073635A3 (en) Automatable artificial immune system (ais)
WO2007108835A3 (en) Automatable artificial immune system (ais)
ES2581277T3 (es) Composición mejorada para inhibir la proliferación de células tumorales
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
Zhang et al. Local delivery of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber scaffold suppress arthritis in rats
Parvizi et al. Development of recombinant collagen‐peptide‐based vehicles for delivery of adipose‐derived stromal cells
JP2014515258A5 (enExample)
Hovhannisyan et al. The role of non-immune cell-derived extracellular vesicles in allergy
AR125461A1 (es) Células presentadoras de antígeno recombinante
CL2022001380A1 (es) Células madre mesenquimales con propiedades terapéuticas mejoradas
MX2021007353A (es) Generación de células t sensibilizadas por organoide (opt) con fenotipo de memoria.
ES2479543T1 (es) Poblaciones celulares que tienen actividad inmunorreguladora, métodos para la preparación y usos de las mismas
WO2019068048A1 (en) INTERMEDIATE NK CELLS DERIVED FROM PLACENTA (PINK) FOR THE TREATMENT OF GLIOBLASTOMA
KR102167819B1 (ko) 코 하비갑개 유래 중간엽 줄기세포를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 약학적 조성물
BR112021010804A2 (pt) Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas